Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits
J. Clin. Invest. Lea Scheppke, et al. 118:2337 doi:10.1172/JCI33361 [Go to this article.]

Figure 1
PP1 inhibits VEGF-induced retinal vascular permeability. (A–C) Fluorescein dextran–perfused retinal whole mounts from mice that received systemic vehicle and either intravitreal PBS (A) or VEGF (B) versus systemic PP1 and intravitreal VEGF (C). Shown is the absence of leakage in eyes given both VEGF and PP1 (C, higher magnification) compared with VEGF-treated eyes in the absence of an Src kinase inhibitor, which have areas of both focal and diffuse dextran extravasation (B). (D) Vascular permeability as measured by retinal EB dye accumulation, with and without drug treatments. Error bars indicate SEM. n = eyes per group. EB leakage: intravitreal PBS and systemic vehicle, 2.81 ± 0.51 (SEM). VEGF/vehicle, 8.69 ± 1.43; PBS/SKI-606, 1.62 ± 0.37; VEGF/SKI-606, 1.98 ± 0.43; PBS/PP1, 1.38 ± 0.27; VEGF/PP1, 1.85+0.46 Retinal vascular permeability factor is a measure of [concentration of EB dye in the retina]/[concentration of EB dye in the plasma × circulation time]. **P < 0.01. Original magnification, ×4 (A, B); ×10 (C).